Current approaches to medullary thyroid carcinoma, sporadic and familial

Elizabeth Fialkowski, Jeffrey F. Moley

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Medullary thyroid carcinoma (MTC) is a rare malignancy of the thyroid C cells. It occurs in hereditary (25% of cases) and sporadic forms, and aggressiveness is related to the clinical presentation (hereditary vs. sporadic) and the type of RET mutation present. In hereditary cases, early diagnosis makes preventative surgery possible. In established cases, thorough surgical extirpation of the primary tumor and nodal metastases has been the mainstay of treatment. Radioactive iodine, external beam radiation therapy (EBRT), and conventional chemotherapy have not been effective. Newer systemic treatments, with agents that target abnormal RET proteins, hold promise and are being tested in clinical trials for patients with metastatic disease.

Original languageEnglish (US)
Pages (from-to)737-747
Number of pages11
JournalJournal of Surgical Oncology
Volume94
Issue number8
DOIs
StatePublished - Dec 15 2006
Externally publishedYes

Fingerprint

Iodine
Early Diagnosis
Neoplasms
Thyroid Gland
Radiotherapy
Clinical Trials
Neoplasm Metastasis
Drug Therapy
Mutation
Therapeutics
Proteins
Familial medullary thyroid carcinoma
Medullary Thyroid cancer

Keywords

  • Chemotherapy
  • MTC
  • Multiple endocrine neoplasia
  • RET tyrosine kinase
  • Thyroid cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Current approaches to medullary thyroid carcinoma, sporadic and familial. / Fialkowski, Elizabeth; Moley, Jeffrey F.

In: Journal of Surgical Oncology, Vol. 94, No. 8, 15.12.2006, p. 737-747.

Research output: Contribution to journalArticle

@article{83cc797eb3384f1fa646c2d64723d1c6,
title = "Current approaches to medullary thyroid carcinoma, sporadic and familial",
abstract = "Medullary thyroid carcinoma (MTC) is a rare malignancy of the thyroid C cells. It occurs in hereditary (25{\%} of cases) and sporadic forms, and aggressiveness is related to the clinical presentation (hereditary vs. sporadic) and the type of RET mutation present. In hereditary cases, early diagnosis makes preventative surgery possible. In established cases, thorough surgical extirpation of the primary tumor and nodal metastases has been the mainstay of treatment. Radioactive iodine, external beam radiation therapy (EBRT), and conventional chemotherapy have not been effective. Newer systemic treatments, with agents that target abnormal RET proteins, hold promise and are being tested in clinical trials for patients with metastatic disease.",
keywords = "Chemotherapy, MTC, Multiple endocrine neoplasia, RET tyrosine kinase, Thyroid cancer",
author = "Elizabeth Fialkowski and Moley, {Jeffrey F.}",
year = "2006",
month = "12",
day = "15",
doi = "10.1002/jso.20690",
language = "English (US)",
volume = "94",
pages = "737--747",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Current approaches to medullary thyroid carcinoma, sporadic and familial

AU - Fialkowski, Elizabeth

AU - Moley, Jeffrey F.

PY - 2006/12/15

Y1 - 2006/12/15

N2 - Medullary thyroid carcinoma (MTC) is a rare malignancy of the thyroid C cells. It occurs in hereditary (25% of cases) and sporadic forms, and aggressiveness is related to the clinical presentation (hereditary vs. sporadic) and the type of RET mutation present. In hereditary cases, early diagnosis makes preventative surgery possible. In established cases, thorough surgical extirpation of the primary tumor and nodal metastases has been the mainstay of treatment. Radioactive iodine, external beam radiation therapy (EBRT), and conventional chemotherapy have not been effective. Newer systemic treatments, with agents that target abnormal RET proteins, hold promise and are being tested in clinical trials for patients with metastatic disease.

AB - Medullary thyroid carcinoma (MTC) is a rare malignancy of the thyroid C cells. It occurs in hereditary (25% of cases) and sporadic forms, and aggressiveness is related to the clinical presentation (hereditary vs. sporadic) and the type of RET mutation present. In hereditary cases, early diagnosis makes preventative surgery possible. In established cases, thorough surgical extirpation of the primary tumor and nodal metastases has been the mainstay of treatment. Radioactive iodine, external beam radiation therapy (EBRT), and conventional chemotherapy have not been effective. Newer systemic treatments, with agents that target abnormal RET proteins, hold promise and are being tested in clinical trials for patients with metastatic disease.

KW - Chemotherapy

KW - MTC

KW - Multiple endocrine neoplasia

KW - RET tyrosine kinase

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=33845420535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845420535&partnerID=8YFLogxK

U2 - 10.1002/jso.20690

DO - 10.1002/jso.20690

M3 - Article

C2 - 17131404

AN - SCOPUS:33845420535

VL - 94

SP - 737

EP - 747

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 8

ER -